Adaptimmune Reports $4M in Q1 Sales

By Ahmed Jameison • Tuesday, May 13 15:19 • Permanent Link

Adaptimmune Therapeutics PLC, a company specializing in cell therapy for solid tumor cancers, has reported its financial results for the first quarter ending March 31, 2025. The company's Tecelra launch has seen significant progress, with 28 authorized treatment centers now accepting referrals and 21 patients aphresed, resulting in 14 doses invoiced, generating $4.0 million in net sales for Q1 2025. The company has provided a 2025 Tecelra full year sales guidance of $35-$45 million, reflecting the acceleration of sales and robust patient pipeline.

The company's total liquidity as of March 31, 2025, stood at $60 million, compared to $151.6 million as of December 31, 2024. Revenue for the first quarter of 2025 was $7.3 million, a significant increase from $5.7 million in the same period in 2024, primarily driven by the $4.0 million in product sales following the FDA approval of Tecelra in August 2024. The company has also seen a decrease in research and development expenses, which were $28.9 million for the first quarter of 2025, compared to $35.2 million for the same period in 2024.

Adaptimmune's net loss attributable to holders of the company's ordinary shares for the first quarter of 2025 was $47.6 million, a slight improvement from $48.5 million in the equivalent period in 2024.

The company is also making progress with its Lete-cel product, with pivotal trials meeting primary endpoints and on track to initiate rolling BLA submission in late 2025, with approval anticipated in 2026. The company is also reviewing strategic options with TD Cowen and has made a $25 million debt principal paydown in Q1 2025.

Adrian Rawcliffe, Adaptimmune's Chief Executive Officer, expressed confidence in the team's ability to identify eligible patients, manufacture personalized engineered T cell treatments, and deliver products, paving the way for a successful business platform for cell therapies in solid tumors.

The company's webcast and replay can be accessed at https://www.gowebcasting.com/14032, and call-in information is available for those interested in participating.

Adaptimmune is focused on redefining cancer treatment through its unique engineered T cell receptor (TCR) platform, aiming to develop personalized medicines to target and destroy difficult-to-treat solid tumor cancers. The market has reacted to these announcements by moving the company's shares 0.89% to a price of $0.2952. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.